December 20, 2024

Shanghai Ranking of Academic Subjects: Outstanding Placings for Universität Heidelberg

Shanghai Ranking of Academic Subjects: Outstanding Placings for Universität Heidelberg

Clinical medicine internationally in 17th position – medical technology ranks 16th worldwide

With medical technology and clinical medicine, Heidelberg University is among the best representatives of the medical sciences worldwide. In the 2024 Global Ranking of Academic Subjects, medical technology ranks 16th internationally, which means second place in Germany. Clinical medicine moves up one place internationally to 17th position and continues to hold the top position in Germany. The biological sciences are once again at the top of the list in Germany and, as in the previous year, have improved in the international comparison. After a jump of five places, they are now ranked 38th worldwide.

Human biological sciences in Heidelberg are among the 100 best representatives of this subject internationally. Like the biological sciences, they are classed under life sciences and place in the 51 to 75 ranking group internationally, taking third place in Germany. Among the “top 100” subjects in the natural sciences are, for the first time, earth sciences (76 to 100 internationally, fourth in Germany), as well as physics, which also comes in the 76 to 100 ranking group internationally and places second in the national comparison. For the first time included in the ranking is the subject remote sensing (76 to 100), which is classed in the engineering group of subjects. 

The Subject Ranking appeared in November 2024 and is part of the Academic Ranking of World Universities, also called the Shanghai Ranking. It covers a total of five academic areas to which the ranked subjects are assigned. Compared to the previous year, the methodology has been changed and four new indicators have been added to the previous five, which include, above all, publication data as well as prizes and awards won at a university. The new indicators include, for instance, the number of highly cited researchers or the number of editors of international journals. The individual indicators are weighted differently depending on the subject and are used across five different categories.

In the overall Shanghai Ranking published in August this year, Heidelberg University took third place in Germany, ranking 14th in Europe and 50th internationally.

Further information

Our latest News

discover more
New Publication from Sciomics GmbH: Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells

New Publication from Sciomics GmbH: Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells

Nagel, A.; Hass, E.W.; Hayes, H.; Huelbes, L.; Oliveira, S.; Hardin, H.M.; Marasigan, M.; Nisenbaum, E.; Misztal, C.; Telischi, F.F.; et al. Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells. Int. J. Mol. Sci. 2026, 27, 2636. https://doi.org/10.3390/ijms27062636 https://www.mdpi.com/1422-0067/27/6/2636 Simple Summary This study focuses on the action of fimepinostat, a dual histone deacetylase (HDAC)/phosphosphoinositide-3 kinase […]

Fraunhofer IPA wins the “euRobotics Technology Transfer Award” together with Trumpf and Lorch

Fraunhofer IPA wins the “euRobotics Technology Transfer Award” together with Trumpf and Lorch

Technology transfer that works: At the “European Robotics Forum” (ERF) in late March, the trio of applicants won the prestigious award. The award recognizes research that has found its way into industrial applications. The application focused on a “no-code” solution that allows companies to deploy cobots without specialized knowledge or significant welding effort, even for […]

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Paris and Tarrytown, NY, April 13, 2026. The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged two to 11 years with inadequate response to histamine-1 […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp